Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15209784 | 0.85 | SMN1; SMN2 (0.50) | LMNAKDM4ESLC9A1MAPTALDH1A1 | |
| SCHEMBL15218575 | 0.83 | NPY5R (0.50) | SLC9A1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL19187348 | 0.83 | SLC9A1 (0.41) | LMNAKDM4ESLC9A1MAPTALDH1A1 | |
| SCHEMBL19188166 | 0.82 | SLC9A1 (0.43) | LMNAKDM4ESLC9A1MAPTALDH1A1 | |
| SCHEMBL20028704 | 0.81 | SLC9A1 (0.47) | LMNASLC9A1MAPTALDH1A1MEN1 | |
| SCHEMBL19188095 | 0.78 | MET (0.43) | LMNAKDM4ESLC9A1GAAMAPT | |
| SCHEMBL15232733 | 0.78 | SLC9A1 (0.45) | LMNASLC9A1MAPTALDH1A1MEN1 | |
| SCHEMBL21882083 | 0.77 | PDE10A (0.49) | LMNASLC9A1GAAMAPTALDH1A1 | |
| SCHEMBL20028705 | 0.76 | ALDH1A1 (0.46) | LMNASLC9A1MAPTALDH1A1KMT2A | |
| SCHEMBL15209967 | 0.75 | CYP2C9 (0.46) | LMNAMAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4268820-A2 | COMBINATION THERAPY OF C-C CHEMOKINE RECEPTOR-9 (CCR9) INHIBITORS AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ChemoCentryx, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| US-8916601-B2 | Aza-aryl 1H-pyrazol-1-YL benzene sulfonamides | CHEMOCENTRYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130225580-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225580-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES | CCR9, CCR1, CCR3 | LMNA 4475/4885KDM4E 2015/4885EGFR 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.